Abstract
The above-mentioned guideline by Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, and Kawamori R (J Clin Endo Metab. 2008;93(10): 3671–3689; doi: 10.1210/jc.2008-0222) was retired and replaced by the following publication: Rosenzweig JL, Bakris GL, Berglund LF, Hivert M-F, Horton ES, Kalyani RR, Murad MH, Vergès BL. Primary Prevention of ASCVD and T2DM in Patients at Metabolic Risk: An Endocrine Society Clinical Practice Guideline. J Clin Endo Metab. 2019;104(9): 3939–3985; doi: 10.1210/jc.2019-01338 doi: 10.1210/jc.2008-0222.
| Original language | English (US) |
|---|---|
| Pages (from-to) | E2847 |
| Journal | Journal of Clinical Endocrinology and Metabolism |
| Volume | 106 |
| Issue number | 7 |
| DOIs |
|
| State | Published - Jul 1 2021 |
ASJC Scopus subject areas
- Biochemistry, medical
- Endocrinology
- Biochemistry
- Clinical Biochemistry
- Endocrinology, Diabetes and Metabolism
Fingerprint
Dive into the research topics of 'Erratum: Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: An endocrine society clinical practice guideline (The Journal of Clinical Endocrinology and Metabolism (2019) 104:9 (3939-3985) DOI: 10.1210/jc.2019-01338)'. Together they form a unique fingerprint.Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS